{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:46:41Z","timestamp":1788871601735,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T00:00:00Z","timestamp":1418083200000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.diabres.2014.08.024","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T00:22:13Z","timestamp":1410826933000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-na\u00efve people with poorly controlled type 2 diabetes"],"prefix":"10.1016","volume":"106","author":[{"given":"Asrul Akmal","family":"Shafie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranya","family":"Baabbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hammerby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Home","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2014.08.024_bib0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence in adults for 2013 and projections for 2035 for the IDF Diabetes Atlas","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2014.08.024_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2012.10.001","article-title":"Global guideline for type 2, diabetes","volume":"104","author":"International Diabetes Federation","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2014.08.024_bib0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2014.08.024_bib0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.diabres.2011.10.021","article-title":"An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-western countries: the A1cheive study","volume":"94","author":"Home","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2014.08.024_bib0025","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1742-1241.2009.02002.x","article-title":"Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30\/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study","volume":"63","author":"Valensi","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2014.08.024_bib0030","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.clinthera.2009.08.011","article-title":"Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a metaanalysis","volume":"31","author":"Davidson","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabres.2014.08.024_bib0035","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1185\/03007995.2010.485087","article-title":"Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials","volume":"26","author":"Fonseca","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2014.08.024_bib0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.diabres.2011.10.020","article-title":"Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study","volume":"94","author":"Shah","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2014.08.024_bib0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3111\/13696991003723999","article-title":"Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting","volume":"13","author":"Palmer","year":"2010","journal-title":"J Med Econ"},{"key":"10.1016\/j.diabres.2014.08.024_bib0050","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1185\/030079905X74989","article-title":"Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30\/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting","volume":"21","author":"Valentine","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2014.08.024_bib0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-7525-5-8","article-title":"Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues","volume":"5","author":"Brod","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2014.08.024_bib0060","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0168-8227(10)70004-8","article-title":"Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries: can locally generated observational study data overcome methodological limitations?","volume":"88","author":"Baik","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2014.08.024_bib0065","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/10899580-000000000-00000","article-title":"Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules","volume":"27","author":"Shillcutt","year":"2009","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.diabres.2014.08.024_bib0070","unstructured":"World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization, 2003."},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2014.08.024_bib0075","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0168-8227(10)70003-6","article-title":"The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice","volume":"88","author":"Shah","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.diabres.2014.08.024_bib0080","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.diabres.2013.11.008","article-title":"Diabetes in the Middle-East and North Africa: an update","volume":"103","author":"Majeed","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2014.08.024_bib0085","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1185\/030079904X2006","article-title":"Validation of the CORE Diabetes Model against epidemiological and clinical studies","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2014.08.024_bib0090","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","article-title":"The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2014.08.024_bib0095","doi-asserted-by":"crossref","first-page":"A178","DOI":"10.1016\/j.jval.2012.03.966","article-title":"Direct medical costs of diabetes-related complications in Saudi Arabia","volume":"15","author":"Hnoosh","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2014.08.024_bib0100","doi-asserted-by":"crossref","first-page":"A179","DOI":"10.1016\/j.jval.2012.03.968","article-title":"Direct medical management costs of diabetes-related complications in Algeria","volume":"15","author":"Hnoosh","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2014.08.024_bib0105","first-page":"A662","article-title":"Estimating the direct medical costs associated with diabetes-related complications in Indonesia","volume":"15","author":"Todorova","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2014.08.024_bib0110","first-page":"A662","article-title":"Direct medical costs of diabetes-related complications in India","volume":"15","author":"Todorova","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2014.08.024_bib0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","article-title":"Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation","volume":"6","author":"Briggs","year":"1997","journal-title":"Health Econ"},{"key":"10.1016\/j.diabres.2014.08.024_bib0120","unstructured":"The World Bank. World Bank Open Data. 2012. Available from: http:\/\/data.worldbank.org \/(accessed02 January 2014)."},{"key":"10.1016\/j.diabres.2014.08.024_bib0125","unstructured":"World Health Organization. CHOosing Interventions that are Cost-Effective (WHO-CHOICE). 2009. Available from: http:\/\/www.who.int\/choice\/costs\/CER_thresholds\/en\/index.html (accessed 02 January 2014)."},{"key":"10.1016\/j.diabres.2014.08.024_bib0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/diacare.28.1.59","article-title":"Predictors of health care costs in adults with diabetes","volume":"28","author":"Gilmer","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.024_bib0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2337\/diacare.24.1.51","article-title":"Potential short-term economic benefits of improved glycemic control: a managed care perspective","volume":"24","author":"Menzin","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.024_bib0140","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3111\/13696990802589122","article-title":"Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia","volume":"11","author":"Ali","year":"2008","journal-title":"J Med Econ"},{"key":"10.1016\/j.diabres.2014.08.024_bib0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc06-0144","article-title":"Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India","volume":"30","author":"Ramachandran","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.024_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2230-8229.108174","article-title":"Economic costs of diabetes in Saudi Arabia","volume":"20","author":"Alhowaish","year":"2013","journal-title":"J Family Community Med"},{"key":"10.1016\/j.diabres.2014.08.024_bib0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1744-8603-9-63","article-title":"Challenges in diabetes management in Indonesia: a literature review","volume":"9","author":"Soewondo","year":"2013","journal-title":"Global Health"},{"key":"10.1016\/j.diabres.2014.08.024_bib0160","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diabres.2010.01.026","article-title":"Global healthcare expenditure on diabetes for 2010 and 2030","volume":"87","author":"Zhang","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2014.08.024_bib0165","first-page":"421","article-title":"Medical costs associated with type 2 diabetes complications and comorbidities","volume":"19","author":"Li","year":"2013","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.diabres.2014.08.024_bib0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1463-1326.2006.00581.x","article-title":"Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70\/30 vs. insulin glargine in the US","volume":"9","author":"Ray","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2014.08.024_bib0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12325-008-0069-z","article-title":"Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes","volume":"25","author":"Valentine","year":"2008","journal-title":"Adv Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.diabres.2014.08.024_bib0180","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1111\/j.1524-4733.2009.00628.x","article-title":"Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.diabres.2014.08.024_bib0185","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s12325-008-0080-4","article-title":"Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China","volume":"25","author":"Palmer","year":"2008","journal-title":"Adv Ther"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714003891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714003891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:06:13Z","timestamp":1759172773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822714003891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0168822714003891"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2014.08.024","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-na\u00efve people with poorly controlled type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2014.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}